This interview brings us to the end of a throwback mini-series that I’ve been releasing over the past few months with some of my favorite Medsider guests of all time.

On this particular episode, I chatted with Rich Ferrari, Managing Director of De Novo Ventures, and one of the most well-known VCs in the Medtech space. Here are some of the points we covered:

• Novel ways to fund early-stage medical device companies.
• The metrics that are most important when it comes to early-stage versus late-stage medtech investing.
• Why does the FDA “runway” seem to get longer and longer over time?
• How Rich identifies and validates whether an idea is truly disruptive.

Download the transcript here.